767 related articles for article (PubMed ID: 32809100)
1. Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.
Sourris KC; Watson A; Jandeleit-Dahm K
Handb Exp Pharmacol; 2021; 264():395-423. PubMed ID: 32809100
[TBL] [Abstract][Full Text] [Related]
2. A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches?
Sourris KC; Harcourt BE; Forbes JM
Am J Nephrol; 2009; 30(4):323-35. PubMed ID: 19556753
[TBL] [Abstract][Full Text] [Related]
3. The Development of Maillard Reaction, and Advanced Glycation End Product (AGE)-Receptor for AGE (RAGE) Signaling Inhibitors as Novel Therapeutic Strategies for Patients with AGE-Related Diseases.
Shen CY; Lu CH; Wu CH; Li KJ; Kuo YM; Hsieh SC; Yu CL
Molecules; 2020 Nov; 25(23):. PubMed ID: 33261212
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A review.
Jud P; Sourij H
Diabetes Res Clin Pract; 2019 Feb; 148():54-63. PubMed ID: 30500546
[TBL] [Abstract][Full Text] [Related]
5. Novel inhibitors of glycation and AGE formation.
Rahbar S
Cell Biochem Biophys; 2007; 48(2-3):147-57. PubMed ID: 17709884
[TBL] [Abstract][Full Text] [Related]
6. [Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus].
Nawroth PP; Bierhaus A; Vogel GE; Hofmann MA; Zumbach M; Wahl P; Ziegler R
Med Klin (Munich); 1999 Jan; 94(1):29-38. PubMed ID: 10081287
[TBL] [Abstract][Full Text] [Related]
7. [Antioxidant and anti-AGE therapeutics: evaluation and perspectives].
Bonnefont-Rousselot D
J Soc Biol; 2001; 195(4):391-8. PubMed ID: 11938556
[TBL] [Abstract][Full Text] [Related]
8. Glycative stress from advanced glycation end products (AGEs) and dicarbonyls: An emerging biological factor in cancer onset and progression.
Lin JA; Wu CH; Lu CC; Hsia SM; Yen GC
Mol Nutr Food Res; 2016 Aug; 60(8):1850-64. PubMed ID: 26774083
[TBL] [Abstract][Full Text] [Related]
9. Modulatory role of HMG-CoA reductase inhibitors and ezetimibe on LDL-AGEs-induced ROS generation and RAGE-associated signalling in HEK-293 Cells.
Nabi R; Alvi SS; Shah A; Chaturvedi CP; Iqbal D; Ahmad S; Khan MS
Life Sci; 2019 Oct; 235():116823. PubMed ID: 31476307
[TBL] [Abstract][Full Text] [Related]
10. Phytochemicals as Potential Inhibitors of Advanced Glycation End Products: Health Aspects and Patent Survey.
Fernandes ACF; Melo JB; Genova VM; Santana ÁL; Macedo G
Recent Adv Food Nutr Agric; 2022 Nov; 13(1):3-16. PubMed ID: 34053432
[TBL] [Abstract][Full Text] [Related]
11. A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure.
Ahmad S; Siddiqui Z; Rehman S; Khan MY; Khan H; Khanum S; Alouffi S; Saeed M
Curr Vasc Pharmacol; 2017; 15(4):352-364. PubMed ID: 28356033
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease.
Reynaert NL; Gopal P; Rutten EPA; Wouters EFM; Schalkwijk CG
Int J Biochem Cell Biol; 2016 Dec; 81(Pt B):403-418. PubMed ID: 27373680
[TBL] [Abstract][Full Text] [Related]
13. Linking RAGE and Nox in diabetic micro- and macrovascular complications.
Koulis C; Watson AMD; Gray SP; Jandeleit-Dahm KA
Diabetes Metab; 2015 Sep; 41(4):272-281. PubMed ID: 26323666
[TBL] [Abstract][Full Text] [Related]
14. Evidence that methylglyoxal and receptor for advanced glycation end products are implicated in bladder dysfunction of obese diabetic
Oliveira AL; Medeiros ML; Ghezzi AC; Dos Santos GA; Mello GC; Mónica FZ; Antunes E
Am J Physiol Renal Physiol; 2023 Oct; 325(4):F436-F447. PubMed ID: 37560771
[TBL] [Abstract][Full Text] [Related]
15. Targeting advanced glycation with pharmaceutical agents: where are we now?
Borg DJ; Forbes JM
Glycoconj J; 2016 Aug; 33(4):653-70. PubMed ID: 27392438
[TBL] [Abstract][Full Text] [Related]
16. Gliclazide alters macrophages polarization state in diabetic atherosclerosis in vitro via blocking AGE-RAGE/TLR4-reactive oxygen species-activated NF-kβ nexus.
Jahan H; Choudhary MI
Eur J Pharmacol; 2021 Mar; 894():173874. PubMed ID: 33460615
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases.
Byun K; Yoo Y; Son M; Lee J; Jeong GB; Park YM; Salekdeh GH; Lee B
Pharmacol Ther; 2017 Sep; 177():44-55. PubMed ID: 28223234
[TBL] [Abstract][Full Text] [Related]
18. Fructose causes endothelial cell damage via activation of advanced glycation end products-receptor system.
Sotokawauchi A; Matsui T; Higashimoto Y; Yamagishi SI
Diab Vasc Dis Res; 2019 Nov; 16(6):556-561. PubMed ID: 31375034
[TBL] [Abstract][Full Text] [Related]
19. AGE/RAGE in diabetic kidney disease and ageing kidney.
Wu XQ; Zhang DD; Wang YN; Tan YQ; Yu XY; Zhao YY
Free Radic Biol Med; 2021 Aug; 171():260-271. PubMed ID: 34019934
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies.
Jandeleit-Dahm KA; Lassila M; Allen TJ
Ann N Y Acad Sci; 2005 Jun; 1043():759-66. PubMed ID: 16037303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
